Gu Mi

1.1k total citations
44 papers, 620 citations indexed

About

Gu Mi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Gu Mi has authored 44 papers receiving a total of 620 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 8 papers in Surgery. Recurrent topics in Gu Mi's work include Cancer Immunotherapy and Biomarkers (13 papers), Colorectal Cancer Treatments and Studies (12 papers) and Gastric Cancer Management and Outcomes (10 papers). Gu Mi is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Colorectal Cancer Treatments and Studies (12 papers) and Gastric Cancer Management and Outcomes (10 papers). Gu Mi collaborates with scholars based in United States, France and Spain. Gu Mi's co-authors include Roy S. Herbst, David Ferry, Ian Chau, Emiliano Calvo, Hendrik‐Tobias Arkenau, Nicolas Penel, Jin Jin, Johanna C. Bendell, Rafael Santana-Dávila and Juan Martín-Liberal and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Gu Mi

38 papers receiving 615 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gu Mi United States	14	440	240	179	105	102	44	620
Larsolof Hafström Sweden	8	227 0.5×	179 0.7×	117 0.7×	167 1.6×	34 0.3×	15	552
Holly Kemberling United States	7	471 1.1×	154 0.6×	125 0.7×	58 0.6×	99 1.0×	9	567
Takumi Onoyama Japan	14	231 0.5×	214 0.9×	230 1.3×	87 0.8×	23 0.2×	55	569
Audrey Hennequin France	11	410 0.9×	154 0.6×	102 0.6×	106 1.0×	195 1.9×	34	561
Juan A. Santamaria‐Barria United States	10	294 0.7×	114 0.5×	94 0.5×	80 0.8×	57 0.6×	33	575
Pedro Luiz Serrano Usón Brazil	14	322 0.7×	144 0.6×	181 1.0×	102 1.0×	29 0.3×	59	584
Teruyuki SAKAGUCHI Japan	7	344 0.8×	329 1.4×	197 1.1×	200 1.9×	15 0.1×	13	651
Yulin Tan China	11	162 0.4×	139 0.6×	73 0.4×	94 0.9×	111 1.1×	29	399
Naoshi Nishida Japan	11	375 0.9×	164 0.7×	217 1.2×	274 2.6×	15 0.1×	26	707
Antonio Cubillo Gracián Spain	15	439 1.0×	136 0.6×	64 0.4×	108 1.0×	97 1.0×	30	697

Countries citing papers authored by Gu Mi

Since Specialization

Citations

This map shows the geographic impact of Gu Mi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gu Mi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gu Mi more than expected).

Fields of papers citing papers by Gu Mi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gu Mi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gu Mi. The network helps show where Gu Mi may publish in the future.

Co-authorship network of co-authors of Gu Mi

This figure shows the co-authorship network connecting the top 25 collaborators of Gu Mi. A scholar is included among the top collaborators of Gu Mi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gu Mi. Gu Mi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

He, Philip, Haijun Ma, Revathi Ananthakrishnan, et al.. (2025). Ensuring Quality and Interpretability of Progression Free Survival and Overall Survival in Oncology Clinical Trials. Therapeutic Innovation & Regulatory Science. 59(6). 1495–1505.

Oh, D-Y., Min‐Hee Ryu, Emiliano Calvo, et al.. (2024). 656P Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)‒SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation results. Annals of Oncology. 35. S518–S518.

Mi, Gu, et al.. (2024). A seamless phase II/III design with dose optimization for oncology drug development. Statistics in Medicine. 43(18). 3383–3402.

Konopleva, Marina, Vijaya Raj Bhatt, Ioannis Mantzaris, et al.. (2023). A Phase I, Single-Arm, Open Label, Dose Escalation, Multicenter Study of Off-the-Shelf Natural Killer (NK) Cells (SAR445419) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML). Blood. 142(Supplement 1). 5972–5972.

Mi, Gu, et al.. (2023). A Multi-Arm Two-Stage (MATS) design for proof-of-concept and dose optimization in early-phase oncology trials. Contemporary Clinical Trials. 132. 107278–107278. 3 indexed citations

Chau, Ian, Nicolas Penel, Andres O. Soriano, et al.. (2020). Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial. Cancers. 12(10). 2985–2985. 22 indexed citations

Bang, Yung‐Jue, Talia Golan, Laëtitia Dahan, et al.. (2020). Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ). European Journal of Cancer. 137. 272–284. 103 indexed citations

Herbst, Roy S., Johanna C. Bendell, Edward Arrowsmith, et al.. (2020). Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC. Journal of Thoracic Oncology. 16(2). 289–298. 44 indexed citations

Mi, Gu. (2017). Enhancement of the adaptive signature design for learning and confirming in a single pivotal trial. Pharmaceutical Statistics. 16(5). 312–321. 2 indexed citations

10.

Genova, Carlo, Mark A. Socinski, Rebecca R. Hozak, et al.. (2017). EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study. Journal of Thoracic Oncology. 13(2). 228–236. 10 indexed citations

11.

Herbst, Roy S., Juan Martín-Liberal, Emiliano Calvo, et al.. (2017). Previously treated advanced NSCLC cohort from a multi-disease phase 1 study of ramucirumab (R) plus pembrolizumab (P): Efficacy and safety data. Annals of Oncology. 28. ii32–ii33. 12 indexed citations

12.

Golan, Talia, Chia‐Chi Lin, Siqing Fu, et al.. (2017). A multi-cohort phase 1 study of ramucirumab plus durvalumab: Preliminary safety and clinical activity in patients with locally advanced and unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology. 28. iii5–iii5. 5 indexed citations

13.

Arkenau, Hendrik‐Tobias, Johanna C. Bendell, Roy S. Herbst, et al.. (2017). Ramucirumab plus pembrolizumab in previously treated advanced or metastatic biliary tract cancer: A multi-disease phase 1 study. Annals of Oncology. 28. iii144–iii145. 2 indexed citations

14.

Herbst, Roy S., Juan Martín-Liberal, Emiliano Calvo, et al.. (2016). Interim safety and clinical activity in patients with advanced NSCLC from a multi-cohort phase 1 study of ramucirumab (R) plus pembrolizumab (P). Annals of Oncology. 27. vi574–vi574. 11 indexed citations

15.

Bang, Yung‐Jue, Laura W. Goff, Jing Yang, et al.. (2016). An open-label, multicenter, phase 1 study of ramucirumab (R) plus durvalumab (D) in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or hepatocellular carcinoma (HCC). Annals of Oncology. 27. vi376–vi376.

16.

Herbst, Roy S., Johanna C. Bendell, Nicolás Isambert, et al.. (2016). A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results.. Journal of Clinical Oncology. 34(15_suppl). 3056–3056. 27 indexed citations

17.

Mi, Gu & Yanming Di. (2015). The Level of Residual Dispersion Variation and the Power of Differential Expression Tests for RNA-Seq Data. PLoS ONE. 10(4). e0120117–e0120117. 1 indexed citations

18.

Mi, Gu. (2013). Extreme short-term prediction of ship motion based on chaotic theory and RBF neural network. Chuanbo lixue. 12 indexed citations

19.

Mi, Gu. (2013). Development and application of SSR markers in Agaricus bisporus. Acta Agriculturae Zhejiangensis. 1 indexed citations

20.

Mi, Gu & Zhibin Liu. (2010). On the Continuity of the Fuzzy Reasoning Models Based on Schweizer-Sklar Operations. Acta Mathematicae Applicatae Sinica English Series.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact